Exploring the Efficacy of Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

A devastating illness that affects millions of people globally is breast cancer. Hormone receptor-positive (HR+) tumors are the most prevalent breast cancer. The peripheral conversion of androgens by the enzyme aromatase is the primary source of estrogen synthesis in postmenopausal women. A group of drugs known as aromatase inhibitors aim to target and block the action of aromatase, which lowers estrogen levels.